Safety And Tolerability Of Subcutaneous MANP In Difficult To Control/Resistant Hypertensive Subjects
Status:
Recruiting
Trial end date:
2022-08-30
Target enrollment:
Participant gender:
Summary
A randomized, double-blind, placebo-controlled multiple ascending dose study in hypertensive
subjects on stable doses of at least three hypertensive drugs for at least 6 weeks prior to
Screening. The study will consist of screening, PK-unit admittance, and safety follow up
periods.
Subjects will be randomized at a 6:2 ratio of either MANP or placebo and will be stratified
by race in each dosage cohort. The entire first Cohort will be given the lowest dosage with
subsequent cohorts progressing sequentially to the higher doses depending on safety and
tolerability of the previous cohort.
Endpoints not related to the safety reviews will be analyzed after the last patient last
visit (LPLV).